Skip to content

Influence of Ribavirin and Interferon on Semen Quality, IRIS Study

Influence of Ribavirin and Interferon on Semen Quality, IRIS Study

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00455832
Acronym
IRIS
Enrollment
23
Registered
2007-04-04
Start date
2006-11-30
Completion date
2011-07-31
Last updated
2012-02-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sperm Motility (Focus of Study)

Keywords

sperm chromatin structure integrity, sperm concentration, sperm motility, sperm morphology, peginterferon, ribavirin, hepatitis C

Brief summary

The aim of this study is to study the effect of peginterferon alpha and ribavirin on spermatozoa.

Detailed description

During and six months after treatment with peginterferon alpha and ribavirin strict use of birth control is recommended (the producers advice two reliable forms) for both men and women because ribavirin has teratogenic and/or embryo-lethal effects in animal studies. In cases of pregnancies during paternal exposure to peginterferon alpha and ribavirin elective termination of the pregnancy is usually recommended. However three cases of births after paternal exposure are reported with no birth defects. Cases of abnormalities after paternal exposure to ribavirin are lacking. Also studies on the influence of ribavirin on sperm in human are lacking. The aim of this study is to study the effect of peginterferon alpha and ribavirin on spermatozoa in men using these medication.

Interventions

PROCEDUREpeginterferon alpha and ribavirin

sperm collection

Sponsors

Erasmus Medical Center
CollaboratorOTHER
Foundation for Liver Research
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
MALE
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* Written informed consent * Treatment with peginterferon and ribavirin in the presence of a chronic Hepatitis C infection

Exclusion criteria

* Preexisting semen abnormalities. * Concurrent use of drugs influencing sperm concentration,motility and morphology. * Less then one million spermatozoa/ml in semen at screening.

Countries

Netherlands

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026